Skip to main content

Table 4 Per-protocol data with no adjustments

From: The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial

 

n-3 PUFA  (n = 58)

  

Control  (n = 56)

   
 

Baseline

Week 24

Difference (CI)

Baseline

Week 24

Difference (CI)

P

Heart rate

63.24

61.73

−1.51 (−2.89; −0.13)

63.39

64.38

0.98 (−0.54; 2.50)

0.02

RR ms

964.14

990.39

26.25 (6.21; 46.30)

964.02

950.53

−13.48 (−35.66; 8.69)

0.01

PNN50 %

11.39

11.65

0.26 (−4.06; 4.58)

15.83

14.37

−1.46 (−4.76; 1.84)

0.52

SDNN ms

51.56

49.36

−2.20 (−9.96; 5.56)

49.71

47.41

−2.30 (−6.79; 2.20)

0.98

RMSSD ms

39.10

37.85

−1.25 (−9.41; 6.91)

39.84

39.15

−0.69 (−6.23; 4.85)

0.91

Peripheral BP Systolic mmHg

137.67

134.29

−3.38 (−7.03; 0.26)

134.41

133.18

−1.23 (−4.59; 2.14)

0.39

Peripheral BP Diastolic mmHg

81.96

80.88

−1.08 (−2.89; 0.74)

82.36

80.92

−1.44 (−3.26; 0.39)

0.78

PWV m/s

7.66

7.61

−0.04 (−0.51;- 0.43)

7.40

7.48

0.08 (−0.33; 0.49)

0.70

Central BP systolic mmHg

114.62

112.17

−2.44 (−5.17; 0.28)

113.29

111.38

−1.91 (−4.77; 0.95)

0.79

Central BP diastolic mmHg

95.50

93.13

−2.37 (−4.49; −0.24)

95.45

94.17

−1.29 (−3.51; 0.94)

0.49

PWA AIx

26.42

27.51

1.12 (−0.56; 2.80)

27.02

25.84

−1.15 (−2.78; 0.47)

0.06

  1. Outcomes presented as means with 95% confidence intervals at baseline and after 24 weeks of supplement for both groups
  2. CI Confidence Interval, P P for difference between the two groups of supplement, PWV Pulse wave velocity, BP blood pressure, AIx central Augmentation Index